U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INEQRMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO
4-30724A
APPLICATION NO.
09/871,367
APPLICANT
KRIWET ET AL.
FILING DATE
MAY 31, 2001

Sheet 1 f 4

# **PECEIVED**

DEC 0 6 2001 Group

TECH CENTER 1600/2900

# U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
Y	AA	4,672,078	6/9/87	Sakai et al.	514	588	7/3/85
	AB	5,352,671	10/4/94	Baumann et al.	514	63	5/9/91
	AC	5,385,907	1/31/95	Asakura et al.	514	291	5/17/93
	AD	5,912,238	6/15/99	Baumann et al.	514	63	7/18/94
	ÆΕ	5,925,649	7/20/99	Hersperber et al.	514	291	10/2/97
	AF	5,939,427	8/17/99	Kagayama et al.	514	291	1/5/98
<del></del>	AG						
	АН						
	AI					1	
	AJ						
	AK						<del></del>
	AL					<u> </u>	

### **FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	C	FFICE	CL/	ASS	SUE	BCLASS	TRAN YES	SLATION NO
(F)	AM	0 184 162	6/11/86	Europe							
	AN	0 315 978	5/17/89	Europe							
· \	AO	0 323 042	7/5/89	Europe			T				
	AP	0 423 714	4/24/91	Europe			$\top$				
N	AQ	0 427 680	5/15/91	Europe					<u>.                                    </u>		

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

V	AR	"Aquadrate-Gream", ABPI Data Sheet Compendium, Datapharm Publications, (Ed. G. Walker), p. 1227 (1993-1994).
8	AS	"Handbook of Pharmaceutical Excipients" (Eds. A. Wade and P. J. Weller) Degussa, Germany (1994), joint publication of American Pharmaceutical Association, Washington, USA, and The Pharmaceutical Press, London, England pp. 367, 379, 424-427, 473.
V	АТ	Aoyama et al., "Successful Treatment of Resistant Facial Lesions of Atopic Dermatitis with 0.1% FK506 Ointment", Br. J. Derm., Vol. 133, pp. 492-500 (1995).

**EXAMINER** 

DATE CONSIDERED

4/19/or

\*EXAMINER: Initiat of reference considered, whether or not citation is in conformance with MPEP 609.1 Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

weral sheets if necessary)

**APPLICATION NO.** 09/871,367 **APPLICANT** KRIWET ET AL.

**FILING DATE** 

MAY 31, 2001

She t2 f4 ATTY, DOCKET NO. RECEIVED

DEC 0 6 2001

TECH CENTER 1600/2900

	47Earra	DOCUMENT NUMBER	FOREIG	IN PATENT DOCUMENTS				
	a a	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATION NO
177	AA	0 465 426	1/8/92	Europe	1			
	AB	0 474 126	3/11/92	Europe (Abstract)				
	AC	0 484 936	5/13/92	Europe				
	AD	0 532 088	3/17/93	Europe				
	AE	0 532,089	3/17/93	Europe				
	AF	0 569 337	11/10/93	Europe				
	AG	0 626 385	11/30/94	Europe		·		
	АН	4-182429	6/30/92	Japan (Abstract)				
	Al	62,223,163	10/1/87	Japan (Abstract)				
	AJ	DE 19549243	6/26/97	German (Abstract)				
	AK	WO 91/13889	9/19/91	PCT				
	AL	WO 91/19495	12/26/91	PCT				
	AM	WO 92/11860	7/23/92	PCT				
	AN	WO 93/05059	3/18/93	PCT				
	AO	WO 94/28894	12/22/94	PCT (Abstract)				
	AP	WO 96/13249	5/9/96	PCT (Abstract)				
W	AQ	WO 97/08182	3/6/97	PCT				
	AR							
	AS							
	AT							
	AU							
	AV							
	AW					1		
	AX.							
	AY							
	AZ				·			
EXAMIN	ER	1		DATE CONSIDERED	Uli	a 1 02		<del></del>

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

### INFORMATION DISCLOSURE CITATION

(Use several sheets if nec ssary)

ATTY. DOCKET NO. 4-30724A APPLICATION NO. 09/871,367 **APPLICANT** KRIWET ET AL. **FILING DATE** MAY 31, 2001

# Sheet 3 of 4 **RECEIVED**

DEC 0 6 2001

TECH CENTER 1600/2900

ALENIS IN	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
MISTRA A	British Nat. Formula, Br. Med. Assoc. and Royal Pharm. Soc., Vol. 36, pp. 478-483, Sect. 13.2.1 (1998).
A	Dermatika (Eds. R. Nieder, J. Ziergenmeyer), Wissenschaftliche Verlagsgesellschaft Stuttgart, pp 271-272 (1992)
A	Dumont et al., "A Tacrolimus-Related Immunosuppressant with Reduced Toxicity", Transplantation Vol. 65, No. 1, pp. 18-26 (1998).
A	Fartasch, "Epidermal Barrier in Disorders of the Skin", Microscopy Research and Technique, Vol. 38, pp. 361-372 (1997).
A	Fiedler, "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende-Gebiete", Editio Canto Verlag Aulendorf, Aulendorf,4th revised and expanded edition, Vol. 2 (1996)
·   A	Friend, "Transdermal Delivery of Levonorgestrel", Medicinal Research Reviews, Vol. 11, No. 1, pp. 49-80 (1991).
A	Gelbe Liste 1998, "Indikationen/Substanzgruppen: Dermatologika, Topische Antipsoriatika und ähnliche Präparate".
A	Hagemann et al., "Topical Treatement by Urea Reduces Epidermal Hyperproliferation and Induce Differentiation in Psoriasis", Acta. Derm. Verereol. (Stockh), Vol. 76, pp. 353-356 (1996).
A	Kalbitz et al., "Modulation der Wirkstoffpenetration in die Haut", Pharmazie, Vol. 51, No. 9, pp. 619 637 (1996).
A	Lodén, "Urea-Containing Moisturizers Influence Barrier Properties of Normal Skin", Arch. Dermato Res., Vol. 288, pp. 103-107 (1996).
A	Matsumoto et al., "Safety Study of AG-1 Cream", Yakuri to Chiryo, Vol. 19, No. 5, pp. 1717-1726 (1991) - CA 115:142123j.
A	Mollison et al., "A Macrolactam Inhibitor of T Helper Type 1 and T Helper Type 2 Cytokine biosynthesis for Topical Treatment of Inflammatory Skin Diseases", J. Inv. Derm., Vol. 112, No. 5, pp. 729-738 (May 1999).
7	Neubert et al., "Wirkstoffpenetration in die Haut und deren Modulation", PZ, Vol. 141, No. 17, pp. 11-16, 18, 21-23, (1996) - [34-00937 & 1996:281550 CAPLUS].
A	Peterson et al., "A Tacrolimus-Related Immunosuppressant with Biochemical Properties Distinct From Those of Tacrolimus", Transplantation, Vol. 65, No. 1, pp. 10-18 (1998).
EXAMINER	DATE CONSIDERED (C/19/1D)

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-30724A APPLICATION NO. 09/871,367 APPLICANT KRIWET ET AL. FILING DATE MAY 31, 2001

# RECEIVED

DEC 0 6 2001

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

Review in Therapeutic Drug Carrier Systems, Vol. 14, No. 4, pp. 455-483 (1997).  Rappersberger et al., "Clearing of Psoriasis by a Novel Immunosuppressive Macrolide", J. Invest. Derm., Vol. 106, No. 4, pp. 701-710, (1996).  Rácz et al., "Wassergehalt der Epidermis nach Salizylasäure- und Harnstoffbehandlung", Hautarz Vol. 40, pp. 61-62 (1980).  Ruzicka et al., "A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis", N. Eng. J. Med. Vol. 337, No. 12, pp. 816-821 (1997).  Schmook et al., "Penetration of Sandimmune (Cyclosporin A) in Rat Skin in vitro - Effects of Penetration Enhancers and Solvents", Skin Pharmacol, Vol. 6, pp. 116-124 (1993).  Takahashi et al., "Effect of Vehicles on Diclofenac permeation across Excised Rat Skin", Biol. Pharm. Bull., Vol. 18, No. 4, pp. 571-575 (1995).
AB Derm., Vol. 106, No. 4, pp. 701-710, (1996).  Rácz et al., "Wassergehalt der Epidermis nach Salizylasäure- und Harnstoffbehandlung", Hautarz Vol. 40, pp. 61-62 (1980).  Ruzicka et al., "A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis", N. Eng. J. Med. Vol. 337, No. 12, pp. 816-821 (1997).  Schmook et al., "Penetration of Sandimmune (Cyclosporin A) in Rat Skin in vitro - Effects of Penetration Enhancers and Solvents", Skin Pharmacol, Vol. 6, pp. 116-124 (1993).  Takahashi et al., "Effect of Vehicles on Diclofenac permeation across Excised Rat Skin", Biol.
AC Vol. 40, pp. 61-62 (1980).  Ruzicka et al., "A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis", N. Eng. J. Med. Vol. 337, No. 12, pp. 816-821 (1997).  Schmook et al., "Penetration of Sandimmune (Cyclosporin A) in Rat Skin in vitro - Effects of Penetration Enhancers and Solvents", Skin Pharmacol, Vol. 6, pp. 116-124 (1993).  Takahashi et al., "Effect of Vehicles on Diclofenac permeation across Excised Rat Skin", Biol.
AD Vol. 337, No. 12, pp. 816-821 (1997).  Schmook et al., "Penetration of Sandimmune (Cyclosporin A) in Rat Skin in vitro - Effects of Penetration Enhancers and Solvents", Skin Pharmacol, Vol. 6, pp. 116-124 (1993).  Takahashi et al., "Effect of Vehicles on Diclofenac permeation across Excised Rat Skin", Biol.
AE Penetration Enhancers and Solvents", Skin Pharmacol, Vol. 6, pp. 116-124 (1993).  Takahashi et al., "Effect of Vehicles on Diclofenac permeation across Excised Rat Skin", Biol.
Tanuma et al., "Clinical Evaluation of Bifonazole for Moccasin-Type Tinea Pedis", Mycoses, Vol. 40, pp. 223-228 (1997).
Torres-Rodriguez et al., "Non-Traumatic Topical Treatment of Onychomycosis with Urea Associated with Bifonazole", Mycoses, Vol. 34, pp. 499-304 (1991).
Wohlrab, "Einführung Neurodermitis und Harnstoff", Hautarzt, Vol. 43, pp. 1-4 (1992).
Wohlrab, "Vehikelabhängigkeit der Harnstoffpenetration in die menschliche Haut", Dermatologica Vol. 169, pp. 53-59 (1984).
Wong et al., "Development of Some New Non-Toxic Biodegradable Dermal Penetration Enhancers", J. Pharm. Sci., Vol. 76, No. 11, p. S59 (1987).
Wong et al., "Unsaturated Cyclic Ureas as New Nontoxic Biodegradable Transdermal Penetration Enhancers I: Systhesis", J. Pharm. Sci., Vol. 77, No. 11, pp. 967-971 (1988).
Wong et al., "Unsaturated Cyclic Ureas as New Non-Toxic Biodegradable Transdermal Penetration AM Enhancers. II. Evaluation Study", International Journal of Pharmaceutics, Vol. 52, pp. 191-202 (1989).
AN

EXAMINER

DATE CONSIDERED

4/19/02

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.